Xeljanz (tofacitinib)

100 % legal and regulated
Secured logistics globally
24/7 track & trace delivery
Safe payment by bank transfer or credit card

We are registered as an independent intermediary for medicines with the Dutch Ministry of Health

Xeljanz (tofacitinib)

How to buy Xeljanz: You can order Xeljanz (tofacitinib) via TheSocialMedwork if the drug has not been approved and/or is not available in the patient's country. TheSocialMedwork - helping patients and doctors access the latest approved medicines and at the lowest price possible worldwide.

Manufacturer Pfizer
Disease Rheumatoid Arthritis
Indication Moderately to severely active rheumatoid arthritis
Mode of Action Inhibitor of Janus kinases (JAKs)
Approval Status EMA approved (EU); FDA approved (USA); TGA approved (AUS)
Strength 5 mg

Who is tofacitinib for?

Xeljanz (tofacitinib) is indicated for the treatment of patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. It may be used as monotherapy or in combination with methotrexate [1] or other nonbiologic disease-modifying antirheumatic drugs [2][3].

Recommended dose

Complete information about Xeljanz (tofacitinib) dosage and administration can be found here: [1][2][3].
The standard dosage is:
  • 5 mg twice daily.
Consult your treating doctor for personalised dosing.

What is tofacitinib and how does it work?

Xeljanz (tofacitinib) is an inhibitor of Janus kinases (JAKs) used to treat adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate [1][2][3].
The active substance in Xeljanz, tofacitinib, works by blocking the action of enzymes known as Janus kinases which play an important role in the process of inflammation and joint damage that occurs in rheumatoid arthritis. By blocking their action, tofacitinib helps reduce the inflammation and other symptoms of the disease [4].

What is tofacitinib's approval status?

Xeljanz (tofacitinib) was approved by, among others:
  • FDA (USA) on November 6, 2012 [5]
  • EMA (EU) on March 22, 2017 [4]
  • TGA (AUS) on February 5, 2015 [3]
for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.
The approvals were based on 6 studies in over 4,200 patients with rheumatoid arthritis which have shown the effectiveness of tofacitinib at reducing joint pain and swelling, improving joint movement and slowing down joint damage [1]. An important measure in patients with rheumatoid arthritis is the ACR 20, 50 or 70 which is a criteria to measure the improvement of patients of 20 %, 50 % or 70 % based on measures as swollen joint count, tender joint count, patient assessment of global status, acute phase reactant (dramatic increase in hepatic synthesis of plasma proteins which accompanies acute phases of tissue injury and inflammation), health professional assessment of global status, physical function, and pain [6].
In the clinical studies patients treated with either 5 or 10 mg Xeljanz (tofacitinib) twice daily had ACR20, ACR50, and ACR70 response rates over two times higher than placebo. Higher ACR20 response rates were observed within 2 weeks compared to placebo and were consistent at 6 and 12 months [2]. Detailed information about the clinical studies can be found here: [1][2][3].
The most commonly reported adverse reactions were upper respiratory tract infections, headache, diarrhea, and nasopharyngitis [1][2][3].
[1] Summary of Product Characteristics [EMA]: Xeljanz (tofacitinib), Pfizer Ltd., Mar. 2017.
[2] Summary of Product Characteristics [FDA]: Xeljanz (tofacitinib), Pfizer Inc., Feb. 2016.
[3] Summary of Product Characteristics [TGA]: Xeljanz (tofacitinib), Pfizer Australia Pty Ltd, Feb. 2017.
[4] EMA. Human Medicines: Xeljanz (tofacitinib), 31/03/2017, cited on 24/05/2017.
[5] Drugs.com. Xeljanz (tofacitinib). (last update: 25/03/2016), cited on 24/05/2017.
[6] Pincus T. The American College of Rheumatology (ACR) Core Data Set and derivative “patient only” indices to assess rheumatoid arthritis. Clin Exp Rheumatol 2005; 23(39):109–113.

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Medicine information contained herein may be time sensitive. The absence of a warning for a given medicine or combination thereof in no way should be construed to indicate that the medicine or combination is safe, effective or appropriate for any given patient. Always consult your treating physician before starting a course of treatment.

How can we help?

★ ★ ★ ★ ★

We've received requests for support from patients and doctors in over 120 countries, and delivered medicines to 6 continents. They've given us a 5 star rating for our service. Read what our friends from around the world are saying...

"My experience has been excellent. TheSocialMedwork were totally knowledgeable about the medicine I was looking for, and how to get it delivered to me quickly and easily. I UNCONDITIONALLY recommend TSM to anyone, it is truly a world-class organisation."

— Charles, USA

"During the transaction process I was very well informed by TheSocialMedwork team. They have put so much effort to ensure the best service was offered to me. Moreover the medicine I ordered was imported two weeks earlier. I highly recommend TheSocialMedwork."

— Tomasz, Poland

"I hope you know how needed you are and what it means to get a prompt, succinct and helpful reply. You are our hero. You have given us realistic hope in obtaining needed drugs in a timely way."

— Regina, US

"TheSocialMedwork were so helpful in getting the right medication to me, expediting its delivery, and keeping in touch. They simply can't do enough to help you. I would not hesitate to recommend TheSocialMedwork to anybody. Lovely people."

— Stephen, UK

"Totally awesome! Keep up the great work you're doing!"

— Dee, Australia

"When the doctor tells you that there are no treatments left to try, search further - there may be new treatments in other countries."

— Charlotte, The Netherlands

"TheSocialMedwork's professional capabilities, kindness and patience deserve our gratitude and respect."

— Haoyu, China

"My daughter died at the age of 21 because she couldn't get the treatment that might have saved her life. Now TheSocialMedwork might be able to help people like Abigail to get the best treatment."

— Frank, Virginia, USA

"The team is highly professional, friendly and will take care of everything. More options for doctor and patients. This service is transparent, unique and necessary. Keep it up!"

— Pa Tric, Germany

"Excellent communication and clarifications given every time when requested. They also provide fantastic support and updates from the start till the end of the process of the medicine provisioning."

— Milos, Serbia & Montenegro

Registered with the Dutch Ministry of Health as an independent intermediary, Registration number 6730 BEM
Registered as a USA Delaware LLC.

Our service uses cookies.